anti-Cystatin C (CST3) Antibodies

Human Cystatin C (CST3) interaction partners

1. Data show that cystatin C was negatively associated with small-for-gestational age infants (SGA).

2. Urinary cystatin-C levels were increased in type 2 diabetic patients with early diabetic nephropathy.

3. Age and cystatin C were found to be significant risk factors for cardiovascular events in a pre-diabetic cohort.

4. Increased cystatin C levels may be associated with enhanced risks of composite endpoints in patients with ST-elevation acute myocardial infarction undergoing elective percutaneous coronary intervention

5. Data suggest that kinetics of degradation/proteolysis versus of aggregation of amyloid beta(1-40) and amyloid beta(1-42) at specific concentrations of amyloid beta, cathepsin B, and cystatin C can be modeled and predicted.

6. Serum CysC, at the time of CRRT (Continuous Renal Replacement Therapy cessation), is an independent predictor of the successful weaning from CRRT in critically ill patients with acute kidney injury.

7. The serum levels of cystatin C and urine NGAL, urine OPN can be used as a good marker for assessing the renal effect of obesity which can lead end stage renal disease in pediatric population.

8. The average of estimated glomerular filtration rate (eGFRave) based on creatinine (eGFRcre) and eGFR based on cystatin C (eGFRcys) best predicted the exacerbation of renal function in allogeneic hematopoietic cell transplantation (allo-HCT).

9. Studied serum Cystatin C as a biomarker in bladder urothelial neoplasm; results found serum Cystatin C not to be a reliable marker in predicting bladder urothelial tumors tumorigenesis and clinicopathological characteristics.

10. bladder cancer (BCa) patients have lower serum cysC concentration than the control group. Serum cysC may be considered as a potential marker of BCa but not its aggressiveness.

11. Postoperative serum Cystatin C, IL-18 and Uric acid after 24h were significantly associated with acute kidney injury

12. Serum CysC is a strong predictor of AKI and the short-term prognosis of CCU patients.

13. Neutrophil gelatinase-associated lipocalin concentrations in the urine and serum on the second day of intensive care unit admission could be used to predict the development of acute kidney injury in the following three to seven days in the intensive care unit; however, the cystatin C concentration did not have predictive value

14. Study demonstrated that the binding of CST3 and PSAP decreased the inhibitory effects of CST3 on proteinase in vitro. The co-localization of both proteins was detected in cultured cells and in Bunina body-containing motor neurons from patients with amyotrophic lateral sclerosis, suggesting that they might be involved in the process of Bunina body formation.

15. elevated cystatin C is independently associated with adverse vascular outcomes in people with suspected or established CAD in terms of all-cause mortality, cardiovascular mortality, and total adverse vascular events [meta-analysis]

16. Cognitive function was significantly and inversely associated with cystatin C and microalbuminuria, in the relatively younger general Japanese population.

17. This paper discusses the current findings regarding the role of Cyst C in cancer progression and the clinical implications emerging from these studies--{review}

18. We enrolled 43 stable coronary artery disease (CAD) male patients to examine the relationship between cystatin C-adiponectin (CysC-APN) complex and coronary plaque characteristics. In multivariate analysis, CysC-APN complex levels were identified as the strongest negative factor for fibrotic components and the strongest positive factor for both necrotic and lipidic plus necrotic components.

19. Urinary cystatin C is an independent risk predictor in patients with acute myocardial infarction.

20. serum Cys-C levels predict renal function in patients with prostate neoplasia, but were not a biomarker for the development of prostate neoplasia, and were not correlated with the clinicopathological characteristics of prostate cancer .

Mouse (Murine) Cystatin C (CST3) interaction partners

1. CysC plays an important regulatory role in combating cell death via the autophagic pathway in atherosclerosis.

2. Data (including data from studies in mutant mice) suggest that up-regulation of Cst3, as observed in plasma of mice with type 2 diabetes, down-regulates insulin signaling and promotes endoplasmic reticulum stress in hepatocytes but not in myotubes.

3. Cystatin C is a potential pathogenic signal triggering neurodegeneration in multiple system atrophy.

4. The neuroprotective activity of CysC against Amyotrophic lateral sclerosis-linked mutant Cu/Zn-superoxide dismutase (SOD1)-mediated toxicity.

5. an important role for macrophages, DC, and ROS in diseases associated with the protease inhibitory activity or amyloidogenic properties of cystatin C.

6. APP expression stimulates NSPC proliferation; this effect is mediated via an increase in cystatin C secretion

7. Cystatin C, a protein targeted to the classical secretory pathway by its signal peptide sequence, is secreted by primary neurons in at least 9 different cystatin C glycoforms associated with exosomes.

8. The lack of cystatin C enhances Collagen-induced arthritis and primarily affects in vivo priming of the immune system

9. Inflammation causes downregulation of cystatin C expression in dendritic cells and reduces serum CstC levels.

10. Data show that the absence of cystatin C reduced epithelial cell apoptosis but increased proliferation in skin.

11. Data show that cystatin C effectively rescues cystatin B loss-of-function mutation, facilitating the reversal of pathophysiological changes and suggesting a novel therapeutic intervention for patients with neurodegenerative disorders.

12. CysC plays a protective role under conditions of neuronal challenge by inducing autophagy via mTOR inhibition

13. Oxidants induce elevated cystatin C production from cardiac myocytes. Cystatin C plays a role in cardiac extracellular matrix remodelling.

14. Data show that cystatin c (CystC) contributes to experimental abdominal aortic aneurysms (AAA) pathogenesis and that lack of CystC favors inflammation in AAA lesions induced in atherosclerotic mice.

15. The embryo's cystatin C and F expression functions as a protective mechanism against the maternal proteinase cathepsin S.

16. Cystatin C through this effect can act as an immunomodulatory molecule.

17. expressed in decidual cultures and the expression is controlled in part by TGF-beta(1) and EGF signaling

18. spatiotemporal up-regulation of cystatin C in the hippocampus is induced by entorhinal deafferentation (perforant path transections)

19. Cystatin C is neither necessary nor sufficient to control expression of major histocompatibility type II complexes and antigen presentation in dendritic cells.

20. In vivo overexpression of human cystatin C does not affect amyloid-beta levels in mice that do not deposit amyloid-beta.

Pig (Porcine) Cystatin C (CST3) interaction partners

1. CST3 may be required to remodel endometrial and placental tissues for close apposition between maternal and fetal vasculatures and to facilitate transplacental transport of gases, micronutrients (amino acids, glucose), and macromolecules (proteins).

Rabbit Cystatin C (CST3) interaction partners

1. Increased production of cystatin C in osteoarthritis synovium does not alleviate synovitis or cartilage pathology.

Cow (Bovine) Cystatin C (CST3) interaction partners

1. Cystatin C in milk basic protein (MBP) is suggested as one of the factors inhibiting bone resorption